Description: Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines and vaccines for livestock and companion animals in the United States, Europe, Africa, the Middle East, Canada, Latin America, and the Asia/Pacific. It provides anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; vaccines comprising biological preparations that prevent diseases of the respiratory, gastrointestinal, and reproductive tracts, as well as induce, a specific immune response; parasiticides, whcih prevent or eliminate external and internal parasites, such as fleas, ticks, and worms; medicated feed additives that provide medicines, nutrients, and probiotics to livestock; and other pharmaceutical products, such as pain and sedation, oncology, and antiemetic products. The company markets its products to veterinarians and livestock producers through its sales representatives, and technical and veterinary operations specialists. Zoetis Inc. is based in Florham Park, New Jersey.
Home Page: www.zoetis.com
ZTS Technical Analysis
10 Sylvan Way
Parsippany,
NJ
07054
United States
Phone:
973 822 7000
Officers
| Name | Title |
|---|---|
| Ms. Kristin C. Peck | CEO & Director |
| Mr. Wetteny N. Joseph | Exec. VP & CFO |
| Ms. Heidi C. Chen | Exec. VP, Gen. Counsel, Corp. Sec. & Bus. Lead of Human Health Diagnostics |
| Mr. Glenn C. David | Exec. VP & Group Pres of U.S. Operations, Global Diagnostics and BioDevices |
| Ms. Roxanne Lagano | Exec. VP and Chief HR Officer & Global Operations |
| Ms. Wafaa Mamilli | EVP, Chief Digital & Tech. Officer, Group Pres for China, Brazil and Preci. Animal Health |
| Mr. Steven Frank | VP of Investor Relations |
| Mr. William Price | VP & Chief Communications Officer |
| Dr. Robert J. Polzer Ph.D. | Exec. VP and Pres of R&D |
| Ms. Jeannette Ferran Astorga | Exec. VP of Corp. Affairs & Communications and Chief Sustainability Officer |
Exchange: NYSE
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 30.1205 |
|---|---|
| Trailing PE: | 35.242 |
| Price-to-Book MRQ: | 15.1706 |
| Price-to-Sales TTM: | 8.6561 |
| IPO Date: | 2013-02-01 |
| Fiscal Year End: | December |
| Full Time Employees: | 12100 |